Product
ALIS
Aliases
Amikacin liposome inhalation suspension, ARIKAYCE®
Name
ARIKAYCE
INN Name
Amikacin
FDA Approved
Yes
2 clinical trials
1 organization
2 indications
1 document
Indication
Mycobacterial InfectionsIndication
NontuberculousClinical trial
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium AviStatus: Completed, Estimated PCD: 2023-05-09
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous MycobactStatus: Recruiting, Estimated PCD: 2023-08-21
Document
DailyMed Label: ARIKAYCEOrganization
Insmed Incorporated